Seoul Yes Hospital’s cutting-edge regenerative therapy research is being led by Hospital Director Kim In-kwon (M.D., Ph.D., Board-Certified Orthopedic Surgeon). Director Kim has extensive clinical experience in the field of orthopedics and recently garnered attention for delivering a commencement address at Seoul National University’s graduation ceremony.

“Based on my extensive clinical experience, I plan to focus on research into cartilage regeneration and cellular recovery using stem cells,” said Dr. Kim. “I will continue this research so that patients with early- to mid-stage knee osteoarthritis can receive more effective treatment.”

Since establishing its research institute in 2023, Seoul Yes Hospital has continuously expanded its research into the treatment of musculoskeletal disorders. Currently, the hospital’s in-house research institute is conducting studies utilizing bone marrow- and fat-derived stem cells, with the goal of applying these findings to the treatment of intractable musculoskeletal disorders.

Additionally, Seoul Yes Hospital has been engaged in academic exchanges with Japan’s Oda Clinic for the past three years and is researching treatment methods that incorporate overseas regenerative medicine technologies. Furthermore, the hospital has further strengthened its research capabilities with the addition of Dr. Cho Seong-hoon, former Director of the Advanced Regenerative Medicine Center at Cha Hospital; Dr. Kim Hyung-gu, former Director of Yongin Davos Hospital; and a research institute director from Cha Hospital in Japan.

Following its designation as an advanced regenerative medicine institution, Seoul Yes Hospital secured treatment safety through approval from the Ministry of Health and Welfare and obtained certification for its cell processing facility at the Good Manufacturing Practice (GMP) level. This has enabled the hospital to establish a one-stop treatment system that encompasses tissue harvesting, cell isolation and concentration, cultivation, and procedures.

Additionally, the hospital has introduced a “bone marrow banking system” to store autologous bone marrow and adipose-derived stem cells for use when needed, continuing its preparations for personalized patient care.

Director Kim emphasized, “Our goal is to develop more effective treatments for patients with intractable musculoskeletal disorders,” adding, “We will continue our research to improve patient access to treatment.”